Welcome to our dedicated page for Turnstone Biologics SEC filings (Ticker: TSBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the next clue about Selected TIL progress or cash runway inside Turnstone Biologics’ 200-page reports can feel overwhelming. Clinical-stage biotech filings pack dense trial protocols, complex R&D accounting, and rapid insider moves—exactly the data you need to judge dilution risk or progress toward pivotal studies.
Stock Titan solves the problem. Our AI digests every Turnstone Biologics annual report 10-K simplified, flags fresh details in each Turnstone Biologics quarterly earnings report 10-Q filing, and explains 8-K material events—often within minutes of hitting EDGAR. Want Turnstone Biologics insider trading Form 4 transactions? We stream Turnstone Biologics Form 4 insider transactions real-time and surface patterns like pre-data-readout buys. The platform answers natural questions investors ask, such as “What does Turnstone Biologics report in their SEC filings?” or “How to read Turnstone Biologics’ 10-K without a PhD?” while keeping jargon to a minimum.
Here’s what you’ll uncover:
- Cash burn trends and R&D milestones in Turnstone Biologics earnings report filing analysis
- Clinical trial disclosures hidden in MD&A sections, now translated by AI
- Turnstone Biologics executive stock transactions Form 4 with instant alerts
- Turnstone Biologics proxy statement executive compensation breakdowns
Whether you’re monitoring dilution risk, decoding immunotherapy progress, or tracking governance, understanding Turnstone Biologics SEC documents with AI removes guesswork. All filing types—10-K, 10-Q, 8-K, S-3, and more—arrive with concise summaries, peer benchmarks, and keyword search so you never miss an update. Turnstone Biologics SEC filings explained simply: that’s the Stock Titan advantage.
Turnstone Biologics Corp (TSBX) has filed a Schedule 14D-9 in response to a proposed acquisition by XOMA Royalty Corporation. The filing, dated June 28, 2025, relates to preliminary communications made before the commencement of a tender offer and includes a press release dated June 27, 2025.
Key details of the transaction:
- The acquisition will be executed through a merger agreement dated June 26, 2025
- XRA 3 Corp, a wholly-owned subsidiary of XOMA, will be the merger vehicle
- The target securities are Common Stock with $0.001 par value per share (CUSIP: 90042W100)
The filing indicates preliminary stage communications, with Sammy Farah, President and CEO of Turnstone Biologics, serving as the authorized representative. Legal counsel is being provided by Cooley LLP. This Schedule 14D-9 represents an important step in the merger process, signaling potential changes in ownership and control of Turnstone Biologics.
XOMA Royalty Corporation has announced plans to commence a tender offer to acquire all outstanding shares of Turnstone Biologics (TSBX), pursuant to a Merger Agreement dated June 26, 2025. This SC TO-C filing represents preliminary communications before the formal tender offer launch.
Key aspects of the transaction:
- XOMA will acquire all issued and outstanding common shares of Turnstone (par value $0.001)
- The deal includes a Contingent Value Rights (CVR) Agreement for potential additional payments to Turnstone stockholders
- Transaction will be executed through XRA 3 Corp, a wholly-owned subsidiary of XOMA
The formal tender offer has not yet commenced. When initiated, XOMA will file a Schedule TO with the SEC, and Turnstone will file a Schedule 14D-9 with their recommendation. Shareholders are advised to review the complete tender offer materials once available through the SEC website or XOMA's investor relations portal.
FAQ
What is the current stock price of Turnstone Biologics (TSBX)?
What is the market cap of Turnstone Biologics (TSBX)?
What is the core focus of Turnstone Biologics Corp?
How does Selected TIL therapy work?
What are the primary clinical programs of the company?
How does Turnstone differentiate itself in the field of immunotherapy?
What makes Turnstone's technology innovative?
Which tumor types are targeted by Turnstone’s therapies?
How is Turnstone positioned within the competitive landscape of oncology?
What should investors know about Turnstone’s operational model?
